Cargando…

Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study

BACKGROUND: Most patients who experience virologic failure (VF) on second line antiretroviral therapy (ART) in low-middle income countries fail due to poor adherence rather than antiretroviral resistance. A simple adherence tool designed to detect VF would conserve resources by rationally limiting n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Court, Richard, Leisegang, Rory, Stewart, Annemie, Sunpath, Henry, Murphy, Richard, Winternheimer, Philip, Ally, Mashuda, Maartens, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266950/ https://www.ncbi.nlm.nih.gov/pubmed/25472544 http://dx.doi.org/10.1186/s12879-014-0664-3

Ejemplares similares

Second-Line Antiretroviral Therapy in Sub-Saharan Africa: It Is Time to Mind the Gaps
por: Murphy, Richard A., et al.
Publicado: (2017)

A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy
por: Cohe, Karen, et al.
Publicado: (2019)

Pediatric Response to Second-Line Antiretroviral Therapy in South Africa
por: Zanoni, Brian C., et al.
Publicado: (2012)

Factors Influencing Retention in Care after Starting Antiretroviral Therapy in a Rural South African Programme
por: Boyles, Tom H., et al.
Publicado: (2011)

Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study
por: Meintjes, Graeme, et al.
Publicado: (2015)

Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings
por: Leisegang, Rory, et al.
Publicado: (2010)

A Novel Markov Model Projecting Costs and Outcomes of Providing Antiretroviral Therapy to Public Patients in Private Practices versus Public Clinics in South Africa
por: Leisegang, Rory, et al.
Publicado: (2013)

Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
por: Leisegang, Rory, et al.
Publicado: (2009)

Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy
por: Karamchand, Sumanth, et al.
Publicado: (2016)

Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?
por: Orrell, Catherine, et al.
Publicado: (2017)

Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence
por: Nachega, Jean B, et al.
Publicado: (2012)

Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda
por: Musana, Hellen, et al.
Publicado: (2021)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
por: Mahomed, Kairoonisha, et al.
Publicado: (2020)

Association of First-Line and Second-Line Antiretroviral Therapy Adherence
por: Ramadhani, Habib O., et al.
Publicado: (2014)

Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa
por: Njuguna, Christine, et al.
Publicado: (2016)

Factors Predicting Discordant Virological and Immunological Responses to Antiretroviral Therapy in HIV-1 Clade C Infected Zulu/Xhosa in South Africa
por: Julg, Boris, et al.
Publicado: (2012)

‘Covering the tail’ after stopping efavirenz-based antiretroviral therapy
por: Maartens, Gary
Publicado: (2020)

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial
por: Zhao, Ying, et al.
Publicado: (2023)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
por: Zhao, Ying, et al.
Publicado: (2022)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
por: Keene, Claire M, et al.
Publicado: (2023)

Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug Reaction
por: de Waal, Reneé, et al.
Publicado: (2013)

Adult medical emergency unit presentations due to adverse drug reactions in a setting of high HIV prevalence
por: Mouton, Johannes P., et al.
Publicado: (2021)

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
por: Zhao, Ying, et al.
Publicado: (2021)

Accumulation of Protease Mutations among Patients Failing Second-Line Antiretroviral Therapy and Response to Salvage Therapy in Nigeria
por: Rawizza, Holly E., et al.
Publicado: (2013)

Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy
por: Bisson, Gregory P, et al.
Publicado: (2008)

Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV
por: Boyles, Tom H., et al.
Publicado: (2018)

First-line antiretroviral drug discontinuations in children
por: Fortuin-de Smidt, Melony, et al.
Publicado: (2017)

Can Short-Term Use of Electronic Patient Adherence Monitoring Devices Improve Adherence in Patients Failing Second-Line Antiretroviral Therapy? Evidence from a Pilot Study in Johannesburg, South Africa
por: Evans, Denise, et al.
Publicado: (2016)

Response to second line antiretroviral therapy in India
por: Singh, Anup, et al.
Publicado: (2012)

Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second‐line switches in Swaziland
por: Etoori, David, et al.
Publicado: (2018)

Understanding adherence in virally suppressed and unsuppressed human immunodeficiency virus-positive urban patients on second-line antiretroviral treatment
por: Gumede, Siphamandla B., et al.
Publicado: (2020)

Factors associated with adherence and viral suppression among patients on second-line antiretroviral therapy in an urban HIV program in Kenya
por: Nyaboke, Rose, et al.
Publicado: (2023)

Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa
por: Murphy, Richard A., et al.
Publicado: (2012)

Correction: Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa
por: Murphy, Richard A., et al.
Publicado: (2013)

Prognostic indicators in the World Health Organization’s algorithm for seriously ill HIV-infected inpatients with suspected tuberculosis
por: Griesel, Rulan, et al.
Publicado: (2018)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa
por: Levison, Julie H., et al.
Publicado: (2012)

Incidence and predictors of early loss to follow up among patients initiated on protease inhibitor-based second-line antiretroviral therapy in southwestern Uganda
por: Nuwagira, Edwin, et al.
Publicado: (2021)

Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy
por: Yang, Hailiu, et al.
Publicado: (2012)

Experiencing antiretroviral adherence: helping healthcare staff better understand adherence to paediatric antiretrovirals
por: Phelps, Benjamin R, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_0t48ueetm1v3b0h24ked9aqr6b